Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
A fixed dose combination of vilanterol (adrenergic receptor beta-2 agonist), glycopyrrolate & fluticasone furoate is approved for the treatment of chronic obstructive pulmonary disease.
Lead Product(s): Vilanterol Trifenatate,Glycopyrronium Bromide,Fluticasone Furoate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2023